Bart Neyns
Bart Neyns
Diensthoofd, Medische Oncologie, Universitair Ziekenhuis Brussel
Verified email at uzbrussel.be
Title
Cited by
Cited by
Year
Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
New England Journal of Medicine 372 (26), 2521-2532, 2015
43282015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ...
The lancet oncology 16 (4), 375-384, 2015
22392015
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
E Van Cutsem, M Peeters, S Siena, Y Humblet, A Hendlisz, B Neyns, ...
Journal of clinical oncology 25 (13), 1658-1664, 2007
22292007
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
JD Wolchok, B Neyns, G Linette, S Negrier, J Lutzky, L Thomas, ...
The lancet oncology 11 (2), 155-164, 2010
11892010
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ...
9502018
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
The Lancet 390 (10105), 1853-1862, 2017
8392017
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed …
R Stupp, ME Hegi, B Neyns, R Goldbrunner, U Schlegel, PM Clement, ...
Journal of clinical oncology 28 (16), 2712-2718, 2010
4522010
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma
TT Batchelor, P Mulholland, B Neyns, LB Nabors, M Campone, A Wick, ...
Journal of Clinical Oncology 31 (26), 3212, 2013
4412013
KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
N Engl J Med 372 (26), 2521-2532, 2015
4392015
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ...
The Lancet Oncology 20 (9), 1239-1251, 2019
3842019
Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis
SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ...
Journal of Clinical Oncology 35 (2), 226, 2017
3152017
Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label …
J Larkin, D Minor, S D'Angelo, B Neyns, M Smylie, WH Miller Jr, ...
Journal of clinical oncology 36 (4), 383, 2018
3062018
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
J Larkin, M Del Vecchio, PA Ascierto, I Krajsova, J Schachter, B Neyns, ...
The Lancet Oncology 15 (4), 436-444, 2014
2722014
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients
A Bonehill, AMT Van Nuffel, J Corthals, S Tuyaerts, C Heirman, ...
Clinical Cancer Research 15 (10), 3366-3375, 2009
2262009
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
B Neyns, J Sadones, E Joosens, F Bouttens, L Verbeke, JF Baurain, ...
Annals of oncology 20 (9), 1596-1603, 2009
2172009
Current approaches in dendritic cell generation and future implications for cancer immunotherapy
S Tuyaerts, JL Aerts, J Corthals, B Neyns, C Heirman, K Breckpot, ...
Cancer Immunology, Immunotherapy 56 (10), 1513-1537, 2007
2092007
A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families
T Peelen, M Van Vliet, A Petrij-Bosch, R Mieremet, C Szabo, ...
American journal of human genetics 60 (5), 1041, 1997
2071997
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
E Van Cutsem, S Siena, Y Humblet, JL Canon, J Maurel, E Bajetta, ...
Annals of Oncology 19 (1), 92-98, 2008
1922008
Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma
S Wilgenhof, J Corthals, C Heirman, N van Baren, S Lucas, P Kvistborg, ...
J Clin Oncol 34 (12), 1330-1338, 2016
1882016
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
JD Wolchok, JS Weber, M Maio, B Neyns, K Harmankaya, K Chin, ...
Annals of oncology 24 (8), 2174-2180, 2013
1832013
The system can't perform the operation now. Try again later.
Articles 1–20